Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 78 recruiting now early-phase tilt #65 of 28,707 conditions

Epilepsy: early-phase trial registry

78 of 164 indexed Epilepsy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #65 of 28,707 conditions by registered trial count.

164 US clinical trials · 78 currently recruiting · #65 of 28,707 conditions by registered trial count

Epilepsy: 164 US clinical trials tracked, 78 recruiting.

Epilepsy is the subject of 164 registered US clinical trials on ClinicalTrials.gov, 78 of them currently open to new participants. 21 are in Phase 3-4 (later-stage) and 39 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Neurological Disorders and Stroke (NINDS), running 9 of these trials.

Enrollment posture brief

Registry condition epilepsy

OPEN 78 | RECR 48% | LATE 21 | EARLY 39 | RANK #65 | SPON 9

Nearest open-share peer: Microbial Colonization (48% recruiting · 21 trials)

Epilepsy (this)48%Gastric Cancer45.3%Neoplasms31.3%Parkinson's Disease26.1%Bipolar Disorder22.7%
Open-enrollment share among volume-matched conditions near Epilepsy

Epilepsy lists 78 open slots (48% of 164 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Epilepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Epilepsy is recruiting above its size-band peers.

    78 of 164 indexed trials (47.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Epilepsy trials is spread across many organizations.

    National Institute of Neurological Disorders and Stroke (NINDS) accounts for 9 of 164 trials (5.5%). 95 distinct sponsors appear on at least one study for this condition label.

  3. Most Epilepsy trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 161 trials that report a genuine target (sentinel values excluded). 103 of those (64%) plan for fewer than 100 participants.

  4. Epilepsy research is mostly interventional.

    120 interventional and 44 observational studies make up this index (73.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 123Phase 216Phase 314Phase 47

Open and recent trials

164 total, page 2 of 4

RECRUITING NA 40 participants

Prediction of Anxiety and Memory State

Columbia University

NCT06551090

RECRUITING NA 40 participants

Ear-Seizure Detection (EarSD) Study

Felicia Chu

NCT06598189

RECRUITING NA 40 participants

Computational Neuroscience of Language Processing in the Human Brain

Massachusetts General Hospital

NCT05222594

RECRUITING Phase 1 40 participants

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT02531880

RECRUITING Early Phase 1 40 participants

Effect of Rose Odor Exposure on Ictal Apnea

Vanderbilt University Medical Center

NCT07116421

RECRUITING NA 40 participants

A Room Temperature Atomic Magnetrode System for Telemetry of Epileptic Seizures

University of Colorado, Denver

NCT04515316

RECRUITING Phase 4 30 participants

Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care

University Hospitals Cleveland Medical Center

NCT06346262

RECRUITING 30 participants

PET/MRI/EEG Imaging Study in Epilepsy

Massachusetts General Hospital

NCT06974305

RECRUITING Phase 2 30 participants

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Rapport Therapeutics

NCT07219407

RECRUITING NA 30 participants

VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems

University of Louisville

NCT03953768

RECRUITING NA 30 participants

Invasive Brain-Computer Interfaces for Attention

University of Texas at Austin

NCT06940089

RECRUITING NA 30 participants

Stimulation-Induced Changes in Fronto-Limbic Network

University of Alabama at Birmingham

NCT05854160

RECRUITING NA 30 participants

Intracranial Stimulation Mapping In Epilepsy

University of Minnesota

NCT05290610

RECRUITING Phase 3 26 participants

Lemborexant Treatment of Insomnia Linked to Epilepsy

University of Manitoba

NCT06262594

RECRUITING NA 24 participants

Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application

Dartmouth-Hitchcock Medical Center

NCT06425029

RECRUITING NA 24 participants

Effects of Social Feedback on Intracranial EEG

Trustees of Dartmouth College

NCT06975800

RECRUITING 21 participants

Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome

Royal Devon and Exeter NHS Foundation Trust

NCT05751525

RECRUITING 20 participants

Brain Metabolism Observed at 7 Tesla

University of Texas Southwestern Medical Center

NCT05085704

RECRUITING Phase 1 20 participants

Understanding Ketamine's Dissociative Effects (KD Study)

Stanford University

NCT04861051

RECRUITING NA 16 participants

Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder

The University of Texas Health Science Center, Houston

NCT06695767

RECRUITING NA 16 participants

Effect of Vagal Nerve Stimulation on Gastric Motor Functions

Mayo Clinic

NCT06038929

RECRUITING NA 15 participants

SeizEAR Safety Study

Icahn School of Medicine at Mount Sinai

NCT07088835

RECRUITING NA 10 participants

Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients with Acupuncture Treatment

The University of Texas Health Science Center, Houston

NCT04677751

RECRUITING NA 10 participants

Behavioral and Neuronal Correlates of Human Mood States

Stanford University

NCT06159595

RECRUITING NA 10 participants

Effects of Recorded Music on Clinical and EEG Seizure Activity

Johns Hopkins University

NCT05289934

RECRUITING Phase 1 8 participants

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

NeuroPro Therapeutics

NCT07222878

RECRUITING Phase 1 8 participants

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

NaviFUS Corporation

NCT06388707

RECRUITING Early Phase 1 5 participants

Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery

Sanjeet S. Grewal

NCT06280092

ACTIVE NOT RECRUITING 375 participants

RNS® System Epilepsy Post-Approval Study

NeuroPace

NCT02403843

ACTIVE NOT RECRUITING 300 participants

Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy

University of California, San Francisco

NCT05361070

ACTIVE NOT RECRUITING NA 140 participants

Medtronic Deep Brain Stimulation (DBS) Therapy for Epilepsy Post-Approval Study (EPAS)

MedtronicNeuro

NCT03900468

ACTIVE NOT RECRUITING 105 participants

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

Johns Hopkins University

NCT02694094

ACTIVE NOT RECRUITING Phase 3 100 participants

RNS System NAUTILUS Study

NeuroPace

NCT05147571

ACTIVE NOT RECRUITING 39 participants

Neural Circulatory Control and SUDEP Risk.

Mayo Clinic

NCT02813980

ACTIVE NOT RECRUITING NA 36 participants

Acoustic Stimulation for Seizure Suppression

NYU Langone Health

NCT03198494

ACTIVE NOT RECRUITING Phase 2 24 participants

RNS System LGS Feasibility Study

NeuroPace

NCT05339126

ACTIVE NOT RECRUITING 20 participants

Neuroliten MVP System Clinical Observation Study

Enliten AI

NCT05520476

ACTIVE NOT RECRUITING NA 12 participants

Acute Recording of Stereotyped High-Frequency Oscillations

Mayo Clinic

NCT05439655

ACTIVE NOT RECRUITING NA 5 participants

Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy

Mayo Clinic

NCT03946618

ACTIVE NOT RECRUITING Phase 1 5 participants

BHV-7000 Responsive Neurostimulation System (RNS) Study

Yale University

NCT07125261

COMPLETED Phase 3 767 participants

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

UCB Biosciences

NCT01339559

COMPLETED 565 participants

Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)

Stanford University

NCT01730170

COMPLETED Phase 3 453 participants

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Children's Hospital Medical Center, Cincinnati

NCT00088452

COMPLETED Phase 3 426 participants

Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

UCB Biosciences

NCT00520741

COMPLETED Phase 3 356 participants

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

Eisai

NCT00334958

COMPLETED 303 participants

Brain Blood Flow Studies of Language and Memory

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00001288

COMPLETED NA 268 participants

Epilepsy Adherence in Children and Technology (eACT)

Children's Hospital Medical Center, Cincinnati

NCT03817229

COMPLETED Phase 3 249 participants

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

Upsher-Smith Laboratories

NCT01142193

COMPLETED Phase 3 238 participants

Clobazam in Patients With Lennox-Gastaut Syndrome

Lundbeck

NCT00518713

COMPLETED Phase 1 209 participants

Bioequivalence and Food Effect of 250mg of Lamotrigine XR

GlaxoSmithKline

NCT00605371

← Previous Page 2 of 4 Next →

Phase Distribution

PhaseTrial count
Phase 1 23
Phase 2 16
Phase 3 14
Phase 4 7

Named interventions

Most-linked intervention names on Epilepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
14 trials
Project UPLIFT Behavioral
3 trials
Brivaracetam Drug
3 trials
Levetiracetam Drug
3 trials
Lamotrigine Drug
3 trials
Diazepam Buccal Film Drug
2 trials
oxcarbazepine Drug
2 trials
Individualized Adherence Feedback Report Behavioral
2 trials

US sites by state

Facility locations filed on Epilepsy trials. A trial with sites in several states counts in each.

New York 38 trials
Massachusetts 35 trials
California 31 trials
Florida 30 trials
Minnesota 29 trials
Texas 28 trials
Ohio 26 trials
Maryland 26 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Epilepsy page

164 registered trials, 78 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epilepsy condition card totals 164 registered trials; most-linked intervention Placebo; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.